FIGURE 2.
New ICH during BAVM clinical course after the initiation of treatment by treatment cohort and TNF-α-238 AG genotype (A) or ApoE e2 carrier status (B) on risk of posttreatment ICH.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.